1 / 3

Acquired Hemophilia Therapeutics Market

Acquired hemophilia is a rare autoimmune disease, wherein the bodyu2019s own immune system destroys blood clotting factor and prevents blood clotting, resulting in excessive bleeding.

deepakraj
Download Presentation

Acquired Hemophilia Therapeutics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Acquired Hemophilia Therapeutics Market: Introduction Acquired hemophilia is a rare autoimmune disease, wherein the body’s own immune system destroys blood clotting factor and prevents blood clotting, resulting in excessive bleeding. This is not congenital and develops suddenly due to abnormality in the immune system. Acquired hemophilia is characterized by production of antibodies, also called inhibitors, which attack clotting factor VIII ? a protein required for normal blood clotting, leading to uncontrolled bleeding. Symptoms of acquired hemophilia include prolonged bleeding, hematuria, gastrointestinal bleeding, bruising, and frequent nosebleeds. The causes of acquired hemophilia include autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, and psoriasis. It is also associated with certain medical conditions such as lymphoproliferative diseases, cancer, tumors, and pregnancy. Acquired hemophilia is extremely rare and can be fatal. It can be diagnosed by physical examination describing the bleeding patterns. X-ray or MRI scan can be carried out to detect internal bleeding. Screening coagulation laboratory tests and factor VIII test are preferred to confirm acquired hemophilia. Report hemophilia-therapeutics-market.html Overview: https://www.transparencymarketresearch.com/acquired- Key Drivers, Restrains, and Opportunities of Global Acquired Hemophilia Therapeutics Market Rise in prevalence of autoimmune diseases, increase in the geriatric population, and surge in research expenditure in developing countries are anticipated to propel the market during the forecast period Additionally, high unmet clinical needs in patients with acquired hemophilia, rise in awareness about the condition, and favorable reimbursement policies are major factors projected to drive the global acquired hemophilia therapeutics market However, limited availability of novel treatments for acquired hemophilia in developing countries acts as a major restraint of the global acquired hemophilia therapeutics market North America to Capture Major Share of Global Acquired Hemophilia Therapeutics Market North America is projected to account for major share of the global market during the forecast period. Increase in the geriatric population, high awareness about the disease condition, favorable government support, and improved healthcare infrastructure are major factors that are anticipated to propel the market in North America from 2021 to 2031. According to National Organization for Rare Disorders (NORD) estimates, acquired hemophilia is

  2. likely to affect approximately 0.2 to 1 individuals per 1,000,000/year in the U.S. The acquired hemophilia therapeutics market in Asia Pacific is expected to expand at a high CAGR between 2021 and 2031. This high growth rate can be attributed to increase in research expenditure and rise in awareness about the disease among the population. Request https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=62739 Brochure: Key Players Operating in Global Acquired Hemophilia Therapeutics Market Major players operating in the global acquired hemophilia therapeutics market are listed below: Biogen, Inc. Shire plc Baxter Healthcare Corporation Novo Nordisk A/S BioXcel Corporation Genetech, Inc. Genentech, Inc. Ferring B.V. Pfizer, Inc. Request Customization: https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=6 2739 About Transparency Market Research Transparency Market Research registered at Wilmington, Delaware, United States, is a global market research company providing custom research and consulting services. TMR provides in-depth insights into factors governing demand in the market. It divulges opportunities across various segments based on Source, Application, Sales Channel, and End-Use that will favor growth in the market over the next 9 years. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and

  3. information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ Contact Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com Blog: https://tmrblog.com Email:sales@transparencymarketresearch.com

More Related